-
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Friday, October 7, 2022 - 9:21am | 325Biopharma R&D company Mindset Pharma Inc. (OTCQB: MSSTF) has performed preclinical screening studies and selected MSP-2020 as the lead psychedelic drug clinical candidate and MSP-2003 as the second backup drug candidate, both belonging to its Family 2 next-gen psychedelic drug program done in...
-
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Tuesday, September 27, 2022 - 2:20pm | 513Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. (OTCQB: MSSTF) for an exclusive intellectual property license related to...
-
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Wednesday, September 14, 2022 - 2:26pm | 418Biotech drug discovery firm Mindset Pharma Inc. (OTCQB: MSSTF) develops next-generation psychedelic and non-psychedelic medicines for neuropsychiatric and neurological disorders. To pursue their goal it received scientific advice from the UK Medicines and Healthcare Products Regulatory Agency...
-
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Wednesday, September 7, 2022 - 6:43pm | 308Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds. The company recently announced the creation of three...
-
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Wednesday, August 31, 2022 - 4:41pm | 328Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds. Since its formation, Mindset has the goal of taking drug discovery...
-
Intranasal Psychedelics Platform Is Here, Check Out Mindset's New Development
Thursday, June 30, 2022 - 9:04am | 301In the process of creating optimized next-generation psychedelic medicines for neurological and psychiatric disorders, drug discovery and development company Mindset Pharma Inc. (OTCQB: MSSTF) has developed a novel, patent-pending, intranasal program formulation technology expected to deliver...
-
Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014
Wednesday, June 22, 2022 - 3:56pm | 392Mindset Pharma Inc. (OTCQB: MSSTF), a drug discovery and development company creating next-generation psychedelic medicines for treating neurological and psychiatric disorders, has signed up for a research collaboration with the Centre for Addiction and Mental Health (CAMH), a health teaching and...
-
Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders
Friday, June 10, 2022 - 11:49pm | 458Mindset Pharma Inc. (OTCQB: MSSTF), a drug discovery & development company creating psychedelic medicines to treat neurological and psychiatric disorders, is currently working on four novel families of next-generation psychedelic compounds, as well as an innovative process to chemically...